Clinical Results of Chemotherapy based Treatment in Retinoblastoma Patients: A Single Center Experience
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose: Retinoblastoma is the most common intraocular malignancy in children. Since the 1990s, chemotherapy was indicated for intraocluar disease to reduce the frequency of enucleation and spare the complications associated with external beam radiation. In this study, we analyzed treatment results of retinoblastoma in our institute. Materials and Methods: Datas from children diagnosed with retinoblastoma and treated at Seoul National University Children’s Hospital between 1986 and 2008 were analyzed retrospectively. We utilized cyclophosphamide, vincristine, adriamycin, and methotrexate (CVAM) for OPD-based adjuvant chemotherapy. From 1990, primary chemotherapy was administered to patients with intraocular disease for eyeball-saving and patients received a combination of etoposide, vincristine, cisplatin (or ifosfamide) as a moderately intensive regimen, or a combination of cisplatin, doxorubicin, etoposide, and cycophosphamide (CDEC) as a highly intensive regimen. Results: One hundred eighteen children were analyzed. There were 68 unilateral and 50 bilateral diseases. The median age at diagnosis was 1 year and ReeseEllsworth stage V was the most common stage at the time of diagnosis. All patients were treated by chemotherapy-based multimodality methods, and primary chemotherapy was administered to 80 patients. The 10-year overall and event-free survival rate of all patients were 93.9% and 91.6%, respectively. Two patients who died were in the CDEC regimen group, but there was no significant statistical difference in survival rates by chemotherapy regimens. Fifty-six of 114 eyeballs were saved after primary chemotherapy-based treatment, and the eyeball-saving rate was 49.1%. Six patients relapsed after enucleation and 2 patients were treated successfully after autologous PBSCT. Osteosarcoma occurred in 2 patients as a secondary malignancy, and facial asymmetry after radiotherapy was the most common long-term sequelae. Conclusions: In this study, the overall and event-free survival rates of retinoblastoma were satisfactory and eye-saving was possible with primary chemotherapy. Development of new chemotherapeutic regimens and a team approach are necessary to improve the eyeball-saving rate.
Abstract
Purpose: Retinoblastoma is the most common intraocular malignancy in children. Since the 1990s, chemotherapy was indicated for intraocluar disease to reduce the frequency of enucleation and spare the complications associated with external beam radiation. In this study, we analyzed treatment results of retinoblastoma in our institute. Materials and Methods: Datas from children diagnosed with retinoblastoma and treated at Seoul National University Children’s Hospital between 1986 and 2008 were analyzed retrospectively. We utilized cyclophosphamide, vincristine, adriamycin, and methotrexate (CVAM) for OPD-based adjuvant chemotherapy. From 1990, primary chemotherapy was administered to patients with intraocular disease for eyeball-saving and patients received a combination of etoposide, vincristine, cisplatin (or ifosfamide) as a moderately intensive regimen, or a combination of cisplatin, doxorubicin, etoposide, and cycophosphamide (CDEC) as a highly intensive regimen. Results: One hundred eighteen children were analyzed. There were 68 unilateral and 50 bilateral diseases. The median age at diagnosis was 1 year and ReeseEllsworth stage V was the most common stage at the time of diagnosis. All patients were treated by chemotherapy-based multimodality methods, and primary chemotherapy was administered to 80 patients. The 10-year overall and event-free survival rate of all patients were 93.9% and 91.6%, respectively. Two patients who died were in the CDEC regimen group, but there was no significant statistical difference in survival rates by chemotherapy regimens. Fifty-six of 114 eyeballs were saved after primary chemotherapy-based treatment, and the eyeball-saving rate was 49.1%. Six patients relapsed after enucleation and 2 patients were treated successfully after autologous PBSCT. Osteosarcoma occurred in 2 patients as a secondary malignancy, and facial asymmetry after radiotherapy was the most common long-term sequelae. Conclusions: In this study, the overall and event-free survival rates of retinoblastoma were satisfactory and eye-saving was possible with primary chemotherapy. Development of new chemotherapeutic regimens and a team approach are necessary to improve the eyeball-saving rate.
참고문헌 (21)
- Ellsworth RM, "The practical management of retinoblastoma", Trans Am Ophthalmol Soc, 67, pp.462~534 (1969)
- Phillips C., "Sexton M, Wheeler G, McKenzie J. Retinoblastoma:review of 30 years' experience with external beamradiotherapy", Australas Radiol, 47, pp.226~30 (2003)
- Gombos DS, "Chevez-Barrios AP. Current treatment and managementof retinoblastoma", Curr Oncol Rep, 9, pp.453~8 (2007)
- De Potter P., "Current treatment of retinoblastoma", Curr OpinOphthalmol, 13, pp.331~6 (2002)
- Lee SH, "Tandem high-dose chemotherapy and autologous stem cellrescue in children with bilateral advanced retinoblastoma", Bone Marrow Transplant, 42, pp.385~91 (2008)
- Matsubara H., "A multidisciplinary treatment strategy thatincludes high-dose chemotherapy for metastatic retinoblastomawithout CNS involvement", Bone Marrow Transplant, 35, pp.763~ (2005)
- Yang MH, "A study of the Survival Rate of Childhood Cancer in Korea", Cancer Res Treat, 33, pp.191~ (2001)
- Shields CL, "Shields JA, De Potter P. New treatment modalitiesfor retinoblastoma", Curr Opin Ophthalmol, 7, pp.20~ (1996)
- Abramson DH, "Servodidio CA.Changing trends in the management of retinoblastoma: 1951-1965 vs 1966-1980", J Pediatr Ophthalmol Strabismus, 31, pp.32~ (1994)
- Kim JH, "Clinical result of prolonged primary chemotherapy in retinoblastomapatients", Korean J Ophthalmol, 17, pp.35~43 (2003)
- Reese AB, "The evaluation and current conceptof retinoblastoma therapy", Trans Am Acad Ophthalmol Otolaryngol, 67, pp.164~172 (1963)
- Akiyama K., "Chemotherapyfor retinoblastoma", Ophthalmic Paediatr Genet, 10, pp.111~116 (1989)
- Campinchi R., "Does chemotherapy have a rolein the treatment of retinoblastomas", BullSoc Ophtalmol, 76, pp.17~22 (1976)
- Matthay KK, "Role of myeloablative therapyin improved outcome for high risk neuroblastoma: review ofrecent Children's Cancer Group results", Eur J Cancer, 31A(4), pp.572~575 (1995)
- 한상범, "양안 안구적출술을 받은 망막모세포종 환아들의 임상경과", 대한안과학회지, 48(9), pp.1234~1241 (2007), 대한안과학회
- Chintagumpala M., "Paysse EA, Plon SE,Hurwitz R. Retinoblastoma: review of current management", Oncologist, 12, pp.1237~1246 (2007)
- Lee V., "Globe conserving treatment of the only eye inbilateral retinoblastoma", Br J Ophthalmol, 87, pp.1374~1380 (2003)
- Migdal C., "Bilateral retinoblastoma: the prognosis for vision", Br J Ophthalmol, 67, pp.592~595 (1983)
- Sanders BM, "Retinoblastoma in GreatBritain 1969-80: incidence, treatment, and survival", Br J Ophthalmol, 72, pp.576~583 (1988)
- Suzuki S., "Management of intraocular retinoblastomaand ocular prognosis", Int J Clin Oncol, 9, pp.1~6 (2004)
- Zage PE, "Outcomes of a two-drug chemotherapy regimenfor intraocular retinoblastoma", Pediatr Blood Cancer, 50, pp.567~572 (2008)